CLINICAL TRIALS PROFILE FOR FERRIC CARBOXYMALTOSE
⮫ Send this page by email
✉ Email this page to a colleague
« Back to Dashboard
All Clinical Trials for Ferric Carboxymaltose
Trial ID
Title
Status
Sponsor
Phase
Start Date
Summary
NCT00548691 ↗ Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Completed
American Regent, Inc.
Phase 3
2007-10-01
The Objective of this study is to study the safety of FCM in patients with anemia caused by
chronic kidney failure
NCT00548691 ↗ Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Completed
Luitpold Pharmaceuticals
Phase 3
2007-10-01
The Objective of this study is to study the safety of FCM in patients with anemia caused by
chronic kidney failure
NCT00548860 ↗ Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Completed
American Regent, Inc.
Phase 3
2007-10-01
The Objective of this study is to study the safety of FCM in patients with anemia caused by
Heavy Uterine Bleeding and the Post Partum state.
NCT00548860 ↗ Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Completed
Luitpold Pharmaceuticals
Phase 3
2007-10-01
The Objective of this study is to study the safety of FCM in patients with anemia caused by
Heavy Uterine Bleeding and the Post Partum state.
NCT00703937 ↗ Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
Completed
American Regent, Inc.
Phase 3
2008-07-01
The objective of this study is to evaluate the safety of FCM in patients with anemia who are
not dialysis dependent.
NCT00703937 ↗ Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
Completed
Luitpold Pharmaceuticals
Phase 3
2008-07-01
The objective of this study is to evaluate the safety of FCM in patients with anemia who are
not dialysis dependent.
NCT00704028 ↗ Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
Completed
American Regent, Inc.
Phase 3
2008-06-01
The objective of this study is to evaluate the safety of FCM in patients with anemia who are
not dialysis dependent.
>Trial ID
>Title
>Status
>Phase
>Start Date
>Summary
Clinical Trial Conditions for Ferric Carboxymaltose
Condition Name
Condition Name for Ferric Carboxymaltose
Intervention
Trials
Iron Deficiency Anemia
24
Anemia
23
Iron Deficiency
18
Iron-deficiency
14
[disabled in preview]
0
Subscribe for full access, or try a Trial
Condition MeSH
Condition MeSH for Ferric Carboxymaltose
Intervention
Trials
Anemia, Iron-Deficiency
86
Anemia
65
Deficiency Diseases
20
Heart Failure
19
[disabled in preview]
0
Subscribe for full access, or try a Trial
Clinical Trial Locations for Ferric Carboxymaltose
Trials by Country
Trials by Country for Ferric Carboxymaltose
Location
Trials
United States
147
Germany
24
Poland
16
Spain
15
Canada
10
Subscribe for full access, or try a Trial
Trials by US State
Trials by US State for Ferric Carboxymaltose
Location
Trials
Pennsylvania
13
Florida
10
Texas
9
California
8
North Carolina
6
Subscribe for full access, or try a Trial
Clinical Trial Progress for Ferric Carboxymaltose
Clinical Trial Phase
Clinical Trial Phase for Ferric Carboxymaltose
Clinical Trial Phase
Trials
Phase 4
52
Phase 3
45
Phase 2/Phase 3
1
[disabled in preview]
30
Subscribe for full access, or try a Trial
Clinical Trial Status
Clinical Trial Status for Ferric Carboxymaltose
Clinical Trial Phase
Trials
Completed
56
Recruiting
26
Not yet recruiting
16
[disabled in preview]
29
Subscribe for full access, or try a Trial
Clinical Trial Sponsors for Ferric Carboxymaltose
Sponsor Name
Sponsor Name for Ferric Carboxymaltose
Sponsor
Trials
Vifor Pharma
24
American Regent, Inc.
21
Luitpold Pharmaceuticals
19
[disabled in preview]
25
Subscribe for full access, or try a Trial
Sponsor Type
Sponsor Type for Ferric Carboxymaltose
Sponsor
Trials
Other
147
Industry
108
NIH
1
[disabled in preview]
0
Subscribe for full access, or try a Trial
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
